pembrolizumab,docetaxel
merck
['breast', 'biomarker', 'neopact', 'tnbc']
at 2:45 p.m., hear from in hall d1 as he presents differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in stil-high and stil-low triple-negative breast cancer: biomarker analysis of the neopact trial. #tnbc #asco23 
We are transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our patient care program